| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10147-005-0520-Y |
| P698 | PubMed publication ID | 16369744 |
| P50 | author | Noboru Nakaigawa | Q87997874 |
| P2093 | author name string | Yoshinobu Kubota | |
| Kazumi Noguchi | |||
| Hiroji Uemura | |||
| Takashi Kawahara | |||
| Hisashi Hasumi | |||
| Yasuhide Miyoshi | |||
| Hitoshi Ishiguro | |||
| Jun-ichi Teranishi | |||
| Shinpei Sugiura | |||
| P2860 | cites work | Cancer statistics, 2002 | Q28216788 |
| Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth | Q28323559 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation | Q31805054 | ||
| Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. | Q33767866 | ||
| The central role of angiotensin I-converting enzyme in vertebrate pathophysiology | Q33981551 | ||
| Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? | Q34749837 | ||
| Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth | Q39778121 | ||
| Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. | Q40466820 | ||
| Potentiation of angiotensin II action by corticosteroids in vascular tissue | Q41930372 | ||
| ERK and p38 MAPK, but not NF-kappaB, are critically involved in reactive oxygen species-mediated induction of IL-6 by angiotensin II in cardiac fibroblasts | Q42511347 | ||
| A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. | Q42654377 | ||
| Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. | Q43606239 | ||
| Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer | Q43802386 | ||
| Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer | Q44136736 | ||
| Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial | Q44315403 | ||
| Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. | Q44358734 | ||
| ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. | Q44526996 | ||
| Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor | Q44655998 | ||
| Neuroserpin (PI-12) is upregulated in high-grade prostate cancer and is associated with survival. | Q54679530 | ||
| Activation of human peripheral monocytes by angiotensin II | Q71634273 | ||
| Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy | Q71660676 | ||
| Steroid hormones upregulate rat angiotensin II type 1A receptor gene: role of glucocorticoid responsive elements in rat angiotensin II type 1A promoter | Q71936004 | ||
| Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470; AGM-1470) | Q72093753 | ||
| Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan | Q78954066 | ||
| Regulation of the human tumor necrosis factor-α promoter by angiotensin II and lipopolysaccharide in cardiac fibroblasts: different cis-acting promoter sequences and transcriptional factors | Q79101516 | ||
| P433 | issue | 6 | |
| P304 | page(s) | 405-410 | |
| P577 | publication date | 2005-12-01 | |
| P1433 | published in | International Journal of Clinical Oncology | Q15758148 |
| P1476 | title | Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer | |
| P478 | volume | 10 |
| Q37879662 | 2010 position paper of the Italian Society of Hypertension (SIIA): angiotensin receptor blockers and risk of cancer |
| Q40068278 | Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of gastric cancer xenografts |
| Q36701534 | Angiotensin and systems thinking: wrapping your mind around the big picture |
| Q24626548 | Angiotensin receptor blockers and risk of prostate cancer among United States veterans |
| Q37998961 | Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about? |
| Q51736272 | Chemopreventive effects of angiotensin II receptor type 2 agonist on prostate carcinogenesis by the down-regulation of the androgen receptor. |
| Q36452714 | Current status and perspective of antiangiogenic therapy for cancer: urinary cancer |
| Q34451915 | Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis |
| Q39670866 | Expression and function of ATIP/MTUS1 in human prostate cancer cell lines |
| Q43880703 | Expression and role of the angiotensin II AT2 receptor in human prostate tissue: in search of a new therapeutic option for prostate cancer |
| Q37579080 | Immunohistochemical detection of angiotensin AT 1 and AT 2 receptors in prostate cancer |
| Q34363486 | Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine |
| Q55286689 | Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines. |
| Q35653603 | Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal |
| Q37505197 | Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7) |
| Q37053886 | Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment |
| Q39236911 | Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. |
| Q35681985 | Prognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma |
| Q38981634 | Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma |
| Q39548383 | Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells |
| Q26827221 | Renin-angiotensin system blockade: Its contribution and controversy |
| Q37953334 | Risk of cancer associated with the use of angiotensin II-receptor blockers |
| Q37084550 | Role of renin-angiotensin system in gastric oncogenesis |
| Q47863448 | Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. |
| Q34418476 | Telmisartan inhibits human urological cancer cell growth through early apoptosis |
| Q37042365 | The prince and the pauper. A tale of anticancer targeted agents |
| Q37802186 | The renin-angiotensin system and cancer: old dog, new tricks. |
| Q92802002 | Therapeutic Targeting of Cancer Stem Cells via Modulation of the Renin-Angiotensin System |
| Q39376844 | Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer |
Search more.